Alterations in carbohydrate metabolism and its regulation in PPAR (cid:1) null mouse hearts

Alterations in carbohydrate metabolism and its regulation in PPAR (cid:1) null mouse hearts. Am J Physiol Heart Circ Physiol 2008. a shift from fatty acids (FAs) to carbohydrates (CHOs) is considered beneficial for the diseased heart, it is unclear why subjects with FA (cid:2) -oxidation defects are prone to cardiac decompensation under stress conditions. The present study investigated potential alterations in the myocardial utilization of CHOs for energy production and anaplerosis in 12-wk-old peroxisome proliferator-activating receptor- (cid:1) (PPAR (cid:1) ) null mice (a model of FA (cid:2) -oxidation defects). Carbon-13 methodology was used to assess substrate flux through energy-yielding pathways in hearts perfused ex vivo at two workloads with a physiological substrate mixture mimicking the fed state, and real-time RT-quantitative polymerase chain reaction was used to document the expression of selected metabolic genes. When compared with that from control C57BL/6 mice, isolated working hearts from PPAR (cid:1) null mice displayed an impaired capacity to withstand a rise in preload (mim-icking an increased venous return as it occurs during exercise) as reflected by a 20% decline in the aortic flow rate. At the metabolic level, beyond the expected shift from FA (5-fold down) to CHO (1.5-fold up; P (cid:3) 0.001) at both preloads, PPAR (cid:1) null hearts also displayed 1 ) a significantly greater contribution of exogenous lactate and glucose and/or glycogen (2-fold up) to endogenous pyruvate formation, whereas that of exogenous pyruvate remained unchanged and 2 ) marginal alterations in citric acid cycle-related parameters. The lactate production rate was the only measured parameter that was affected differently by preloads in control and PPAR (cid:1) null mouse hearts, suggesting a restricted reserve for the latter hearts to enhance glycolysis when the energy demand is increased. Alterations in the expression of some glycolysis-related genes suggest potential mechanisms involved in this defective CHO metabolism. Collectively, our data highlight the importance of metabolic alterations in CHO metabolism associated with FA oxidation defects as a factor that may predispose the heart to decompensation under stress conditions even in the fed state.

[1]  C. Des Rosiers,et al.  Medium-chain Fatty Acids as Metabolic Therapy in Cardiac Disease , 2008, Cardiovascular Drugs and Therapy.

[2]  T. Pineau,et al.  Role of oxidative stress in cardiac dysfunction of PPARα−/− mice , 2007 .

[3]  Stefan Neubauer,et al.  The failing heart--an engine out of fuel. , 2007, The New England journal of medicine.

[4]  M. Chandler,et al.  High-fat diet postinfarction enhances mitochondrial function and does not exacerbate left ventricular dysfunction. , 2007, American journal of physiology. Heart and circulatory physiology.

[5]  Kieran Clarke,et al.  A combined 1H-NMR spectroscopy- and mass spectrometry-based metabolomic study of the PPAR-alpha null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. , 2006, Physiological genomics.

[6]  Kevin Stowe,et al.  Storage and oxidation of long‐chain fatty acids in the C57/BL6 mouse heart as measured by NMR spectroscopy , 2006, FEBS letters.

[7]  C. Roe,et al.  Anaplerotic molecules: Current and future , 2006, Journal of Inherited Metabolic Disease.

[8]  J. Balschi,et al.  Decreased Contractile and Metabolic Reserve in Peroxisome Proliferator–Activated Receptor-&agr;–Null Hearts Can Be Rescued by Increasing Glucose Transport and Utilization , 2005, Circulation.

[9]  William C Stanley,et al.  Myocardial substrate metabolism in the normal and failing heart. , 2005, Physiological reviews.

[10]  G. Radda,et al.  PPAR-alpha activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. , 2005, American journal of physiology. Heart and circulatory physiology.

[11]  C. Des Rosiers,et al.  Fatty acid oxidation and its impact on response of spontaneously hypertensive rat hearts to an adrenergic stress: benefits of a medium-chain fatty acid. , 2005, American journal of physiology. Heart and circulatory physiology.

[12]  C. Des Rosiers,et al.  Profiling substrate fluxes in the isolated working mouse heart using 13C-labeled substrates: focusing on the origin and fate of pyruvate and citrate carbons. , 2004, American journal of physiology. Heart and circulatory physiology.

[13]  G. Lopaschuk,et al.  Beneficial Effects of Trimetazidine in Ex Vivo Working Ischemic Hearts Are Due to a Stimulation of Glucose Oxidation Secondary to Inhibition of Long-Chain 3-Ketoacyl Coenzyme A Thiolase , 2003, Circulation research.

[14]  Hitoshi Shimano,et al.  Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes DOI 10.1194/jlr.M100417-JLR200 , 2002, Journal of Lipid Research.

[15]  C. Roe,et al.  Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. , 2002, The Journal of clinical investigation.

[16]  M. Chandler,et al.  Energy Metabolism in the Normal and Failing Heart: Potential for Therapeutic Interventions , 2002, Heart Failure Reviews.

[17]  Robert A. Harris,et al.  Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin. , 2002, Diabetes.

[18]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[19]  P. Razeghi,et al.  Intrinsic Diurnal Variations in Cardiac Metabolism and Contractile Function , 2001, Circulation research.

[20]  H. Taegtmeyer,et al.  Reactivation of Peroxisome Proliferator-activated Receptor α Is Associated with Contractile Dysfunction in Hypertrophied Rat Heart* , 2001, The Journal of Biological Chemistry.

[21]  C. Des Rosiers,et al.  Evidence of separate pathways for lactate uptake and release by the perfused rat heart. , 2001, American journal of physiology. Endocrinology and metabolism.

[22]  G. Shipley,et al.  Uncoupling protein 3 transcription is regulated by peroxisome proliferator‐activated receptor α in the adult rodent heart , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  T. Ono,et al.  Constitutive Regulation of Cardiac Fatty Acid Metabolism through Peroxisome Proliferator-activated Receptor α Associated with Age-dependent Cardiac Toxicity* , 2000, The Journal of Biological Chemistry.

[24]  C. Rosiers,et al.  Citrate release by perfused rat hearts: a window on mitochondrial cataplerosis. , 2000, American journal of physiology. Endocrinology and metabolism.

[25]  A. Okamoto,et al.  Transcriptional Regulation of the ATP Citrate-lyase Gene by Sterol Regulatory Element-binding Proteins* , 2000, The Journal of Biological Chemistry.

[26]  M. Gibala,et al.  Anaplerosis of the citric acid cycle: role in energy metabolism of heart and skeletal muscle. , 2000, Acta physiologica Scandinavica.

[27]  G Kaley,et al.  Myocardial glucose uptake is regulated by nitric oxide via endothelial nitric oxide synthase in Langendorff mouse heart. , 2000, Circulation research.

[28]  D. Rabier,et al.  Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. , 1999, Circulation.

[29]  D. Kelly,et al.  Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. , 1999, The American journal of the medical sciences.

[30]  D. Kelly,et al.  A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Rabier,et al.  Recognition and management of fatty acid oxidation defects: A series of 107 patients , 1999, Journal of Inherited Metabolic Disease.

[32]  D. Kelly,et al.  Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. , 1996, Circulation.

[33]  L. Hue,et al.  Protection against ischemic injury by nonvasoactive concentrations of nitric oxide synthase inhibitors in the perfused rabbit heart. , 1995, Circulation.

[34]  T. Pineau,et al.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.

[35]  E. Saggerson,et al.  Malonyl-CoA metabolism in cardiac myocytes and its relevance to the control of fatty acid oxidation. , 1993, The Biochemical journal.

[36]  D. L. Harris,et al.  Mechanistic stoichiometry of mitochondrial oxidative phosphorylation. , 1991, Biochemistry.

[37]  J. Hiltunen,et al.  Role of NADP+ (corrected)-linked malic enzymes as regulators of the pool size of tricarboxylic acid-cycle intermediates in the perfused rat heart. , 1987, The Biochemical journal.

[38]  A. Zorzano,et al.  Effects of starvation and exercise on concentrations of citrate, hexose phosphates and glycogen in skeletal muscle and heart. Evidence for selective operation of the glucose-fatty acid cycle. , 1985, The Biochemical journal.

[39]  G. Plaut,et al.  The subcellular location of isozymes of NADP-isocitrate dehydrogenase in tissues from pig, ox and rat. , 1983, Biochimica et biophysica acta.

[40]  G. Lopaschuk,et al.  Chronic activation of PPARα is detrimental to cardiac recovery after ischemia , 2006 .

[41]  M. Chandler,et al.  Differential effects of heptanoate and hexanoate on myocardial citric acid cycle intermediates following ischemia-reperfusion. , 2006, Journal of applied physiology.

[42]  D. Kelly,et al.  Mouse models of mitochondrial dysfunction and heart failure. , 2005, Journal of molecular and cellular cardiology.

[43]  C. Des Rosiers,et al.  Differential modulation of citrate synthesis and release by fatty acids in perfused working rat hearts. , 2004, American journal of physiology. Heart and circulatory physiology.

[44]  K. Bulmer,et al.  Peroxisome-proliferator-activated receptor-alpha (PPARalpha) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin. , 2002, The Biochemical journal.

[45]  D. Kelly,et al.  Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. , 2002, Journal of molecular and cellular cardiology.

[46]  G. Gibbons,et al.  Disturbances in the normal regulation of SREBP-sensitive genes in PPAR alpha-deficient mice. , 2001, Journal of lipid research.

[47]  W. Wahli,et al.  Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. , 1999, The Journal of clinical investigation.

[48]  J. Peters,et al.  Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). , 1998, The Journal of biological chemistry.

[49]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.